Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 175 results for "Byetta"

HC Stocks Buzzer: Antares Pharma Inc (NASDAQ:ATRS), Immunomedics, Inc. (NASDAQ:IMMU)
Share Market Updates

Teva settles generic Byetta patent litigation with AstraZeneca

Teva Pharmaceuticals USA, Inc., a leading global pharmaceutical company, announced that the company has settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC (AstraZeneca) relating to ... PharmaBiz, 4 days ago

AstraZeneca, Teva settle Byetta patent suit; generics on their way

Immediately following AstraZeneca's big FluMist setback Thursday, the British pharma has entered into an agreement with Teva that will likely lead to sales losses for another product, Byetta. AstraZeneca and Teva settled patent disputes over the ...
 CPhI.cn1 day ago

Incretin Mimetics Don't Raise Heart Failure Risk

Kaitlin Graves/Mittera Studies have raised concerns about the risk of heart failure with incretin mimetics, a class of type 2 oral and injected medications that includes exenatide (Byetta) , linagliptin (Trajenta), liraglutide (Saxenda and ...
 Diabetes Forecast1 day ago

Victoza Reduces Cardiovascular Death by 22% in Type 2 Diabetes

LEADER results announced at #2016ADA compared to placebo, Victoza reduces risk of cardiovascular death by 22%, plus a 22% reduction in kidney disease and 31% reduction in severe hypoglycemia. More results from this groundbreaking trial. Breaking ...
 diaTribe1 day ago Breaking News from ADA: Victoza Reduces Cardiovascular Death by 22% in Type 2 Diabetes  diaTribe2 weeks ago

BUYINS.NET: AZN, EME, NSC, BOH, MYE, SYNT Expected To Be Up Before Next Earnings Releases

BUYINS.NET / is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and earnings reports.
 TradingCharts.com1 day ago

AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes

By a News Reporter-Staff News Editor at Diabetes Week AstraZeneca announced results from a 10-week randomized, controlled, double-blind, Phase IV study investigating the quality of glucose control with BYDUREON (exenatide extended-release) for ...
 Pharmacy Choice1 day ago AZHelps app puts top AstraZeneca brands, services and info on patients' phones  FiercePharma1 week ago AstraZeneca Introduces AZhelps, an Innovative Savings and Support Program to Help Patients with Their Medicines  Benzinga.com2 weeks ago ASTRAZENECA : Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes  4 Traders2 weeks ago

Step, Michael D.

Michael D. Step is the Chief Executive Officer of Ritter Pharmaceuticals, Inc. Prior to joining Ritter, he was the Senior Vice President of Corporate Development for Santarus, Inc., now a wholly owned subsidiary of Salix Pharmaceuticals, Inc. Mr.
 Wall Street Transcript3 days ago

Intarcia to double to 800 employees as it moves into new digs

Intarcia's implantable drug delivery system for Type 2 diabetes--Courtesy of Intarcia Intarcia is looking to boost its employee count to 400 by the end of this year, and to 800 in 2017 as it preps to move into a new 47,000-square-foot headquarters ...
 FierceMedicalDevices1 week ago Intarcia to Submit its GLP-1 Mini-Pump Implant Device for Type 2 Diabetes to FDA Later this Year  diaTribe1 month ago Promising revolution, Intarcia's diabetes device poised for filing  pharmaphorum1 month ago

VIDEO: FLAT-SUGAR investigators continue to explore role of glucose variability in diabetes-related complications

NEW ORLEANS — In this video exclusive, Irl B. Hirsch, MD, professor of medicine at the University of Washington in Seattle, discusses the motivations behind the FLAT-SUGAR study, new data since the report at last year's American Diabetes ...
 Healio2 weeks ago

Novo's weekly semaglutide bests future rivals Januvia, Bydureon

NEW ORLEANS—Novo Nordisk has staked out a big portion of its pipeline for semaglutide, the once-weekly GLP-1 drug that could follow in the footsteps of its blockbuster daily, Victoza. And this weekend, it rolled out new data pitting the drug ...
 FiercePharma2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less